NASDAQ:CMRX Chimerix (CMRX) Stock Forecast, Price & News $1.39 +0.01 (+0.72%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$1.36▼$1.4450-Day Range$1.10▼$1.4452-Week Range$1.09▼$2.90Volume641,220 shsAverage Volume846,793 shsMarket Capitalization$123.13 millionP/E Ratio0.70Dividend YieldN/APrice Target$8.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Chimerix MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside499.5% Upside$8.33 Price TargetShort InterestHealthy4.99% of Float Sold ShortDividend StrengthN/ASustainability-2.49Upright™ Environmental ScoreNews Sentiment0.51Based on 2 Articles This WeekInsider TradingAcquiring Shares$113,093 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.92) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.96 out of 5 starsMedical Sector51st out of 1,980 stocksPharmaceutical Preparations Industry17th out of 978 stocks 3.5 Analyst's Opinion Consensus RatingChimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.33, Chimerix has a forecasted upside of 499.5% from its current price of $1.39.Amount of Analyst CoverageChimerix has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.99% of the float of Chimerix has been sold short.Short Interest Ratio / Days to CoverChimerix has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chimerix has recently decreased by 9.27%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldChimerix does not currently pay a dividend.Dividend GrowthChimerix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChimerix has received a 58.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pox medications" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Chimerix is -2.49. Previous Next 2.5 News and Social Media Coverage News SentimentChimerix has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Chimerix this week, compared to 3 articles on an average week.Search Interest10 people have searched for CMRX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows1 people have added Chimerix to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chimerix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $113,093.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.20% of the stock of Chimerix is held by insiders.Percentage Held by Institutions58.03% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Chimerix are expected to grow in the coming year, from ($0.92) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chimerix is 0.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Chimerix is 0.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 107.04.Price to Book Value per Share RatioChimerix has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Chimerix (NASDAQ:CMRX) StockChimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.Read More Receive CMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address CMRX Stock News HeadlinesMay 31, 2023 | finance.yahoo.comChimerix to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceMay 25, 2023 | proactiveinvestors.comChimerix's trial treating pediatric brain tumors has a 'relatively high' chance of successJune 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 25, 2023 | finance.yahoo.comChimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White HouseMay 25, 2023 | americanbankingnews.comChimerix (NASDAQ:CMRX) Earns Outperform Rating from Analysts at Robert W. BairdMay 23, 2023 | msn.comBaird Initiates Coverage of Chimerix (CMRX) with Outperform RecommendationMay 21, 2023 | americanbankingnews.comChimerix (NASDAQ:CMRX) Receives New Coverage from Analysts at StockNews.comMay 21, 2023 | americanbankingnews.comMichael T. Andriole Buys 51,700 Shares of Chimerix, Inc. (NASDAQ:CMRX) StockJune 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 14, 2023 | americanbankingnews.comChimerix, Inc. (NASDAQ:CMRX) Director Acquires $19,980.00 in StockMay 8, 2023 | markets.businessinsider.comJonesTrading Sticks to Its Buy Rating for Chimerix (CMRX)May 5, 2023 | finance.yahoo.comChimerix First Quarter 2023 Earnings: Beats ExpectationsMay 4, 2023 | finance.yahoo.comChimerix (CMRX) Reports Q1 Loss, Misses Revenue EstimatesMay 4, 2023 | finance.yahoo.comChimerix Reports First Quarter 2023 Financial Results and Provides Operational UpdateApril 27, 2023 | finance.yahoo.comChimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023April 25, 2023 | americanbankingnews.comBrokerages Set Chimerix, Inc. (NASDAQ:CMRX) PT at $8.50April 19, 2023 | finanznachrichten.deChimerix, Inc.: Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual MeetingApril 18, 2023 | finance.yahoo.comChimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual MeetingApril 2, 2023 | americanbankingnews.comBrokerages Set Chimerix, Inc. (NASDAQ:CMRX) Price Target at $8.50March 31, 2023 | americanbankingnews.comFred A. Middleton Acquires 20,000 Shares of Chimerix, Inc. (NASDAQ:CMRX) StockMarch 15, 2023 | insidermonkey.com5 Best Stocks to Buy for the Next 10 YearsMarch 6, 2023 | finance.yahoo.comChimerix, Inc. (NASDAQ:CMRX) Q4 2022 Earnings Call TranscriptMarch 3, 2023 | msn.comChimerix's Earnings OutlookMarch 3, 2023 | markets.businessinsider.comJonesTrading Keeps Their Buy Rating on Chimerix (CMRX)March 2, 2023 | finance.yahoo.comChimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational UpdateFebruary 28, 2023 | finance.yahoo.comChimerix to Present at Cowen and Company 43rd Annual Health Care ConferenceFebruary 23, 2023 | finance.yahoo.comChimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023See More Headlines CMRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMRX Company Calendar Last Earnings3/02/2023Today6/01/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMRX CUSIPN/A CIK1117480 Webwww.chimerix.com Phone(919) 806-1074Fax919-806-1146Employees87Year Founded2000Price Target and Rating Average Stock Price Forecast$8.33 High Stock Price Forecast$11.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+499.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$2.00 Trailing P/E Ratio0.70 Forward P/E RatioN/A P/E GrowthN/ANet Income$172.17 million Net Margins514.97% Pretax Margin515.07% Return on Equity87.89% Return on Assets79.32% Debt Debt-to-Equity RatioN/A Current Ratio13.68 Quick Ratio13.68 Sales & Book Value Annual Sales$33.82 million Price / Sales3.64 Cash Flow$1.96 per share Price / Cash Flow0.71 Book Value$2.71 per share Price / Book0.51Miscellaneous Outstanding Shares88,580,000Free Float81,320,000Market Cap$123.13 million OptionableOptionable Beta1.15 Social Links Key ExecutivesMichael A. ShermanPresident, Chief Executive Officer & DirectorMichael T. AndrioleChief Financial & Business OfficerRoy W. WareChief Technology & Manufacturing OfficerCaryn BarnettVice President-Clinical OperationsAllen MelemedChief Medical OfficerKey CompetitorsShattuck LabsNASDAQ:STTKMereo BioPharma GroupNASDAQ:MREOGossamer BioNASDAQ:GOSSTrevi TherapeuticsNASDAQ:TRVIPyxis OncologyNASDAQ:PYXSView All CompetitorsInsiders & InstitutionsMichael T AndrioleBought 51,700 shares on 5/18/2023Total: $58,938.00 ($1.14/share)JPMorgan Chase & Co.Sold 143,476 shares on 5/18/2023Ownership: 0.394%Armistice Capital LLCBought 76,000 shares on 5/16/2023Ownership: 3.698%State Street CorpSold 38,165 shares on 5/16/2023Ownership: 2.591%AQR Capital Management LLCBought 216,558 shares on 5/16/2023Ownership: 2.150%View All Insider TransactionsView All Institutional Transactions CMRX Stock - Frequently Asked Questions Should I buy or sell Chimerix stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMRX shares. View CMRX analyst ratings or view top-rated stocks. What is Chimerix's stock price forecast for 2023? 3 brokerages have issued twelve-month price objectives for Chimerix's shares. Their CMRX share price forecasts range from $7.00 to $11.00. On average, they expect the company's stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 499.5% from the stock's current price. View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts. How have CMRX shares performed in 2023? Chimerix's stock was trading at $1.86 at the start of the year. Since then, CMRX stock has decreased by 25.3% and is now trading at $1.39. View the best growth stocks for 2023 here. Are investors shorting Chimerix? Chimerix saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 3,720,000 shares, a decline of 9.3% from the April 30th total of 4,100,000 shares. Based on an average trading volume of 945,700 shares, the days-to-cover ratio is currently 3.9 days. Approximately 5.0% of the company's stock are short sold. View Chimerix's Short Interest. When is Chimerix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our CMRX earnings forecast. How were Chimerix's earnings last quarter? Chimerix, Inc. (NASDAQ:CMRX) released its earnings results on Thursday, March, 2nd. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.24). The biopharmaceutical company earned $0.81 million during the quarter, compared to the consensus estimate of $2.60 million. Chimerix had a net margin of 514.97% and a trailing twelve-month return on equity of 87.89%. During the same quarter last year, the business posted ($0.45) EPS. What ETFs hold Chimerix's stock? ETFs with the largest weight of Chimerix (NASDAQ:CMRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and ETFMG Treatments Testing and Advancements ETF (GERM) and What other stocks do shareholders of Chimerix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD). What is Chimerix's stock symbol? Chimerix trades on the NASDAQ under the ticker symbol "CMRX." Who are Chimerix's major shareholders? Chimerix's stock is owned by many different institutional and retail investors. Top institutional investors include Rubric Capital Management LP (8.28%), BlackRock Inc. (5.52%), Armistice Capital LLC (3.70%), State Street Corp (2.59%), Acadian Asset Management LLC (2.25%) and AQR Capital Management LLC (2.15%). Insiders that own company stock include David Jakeman, Fred A Middleton, Martha J Demski, Michael T Andriole and Robert J Meyer. View institutional ownership trends. How do I buy shares of Chimerix? Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Chimerix's stock price today? One share of CMRX stock can currently be purchased for approximately $1.39. How much money does Chimerix make? Chimerix (NASDAQ:CMRX) has a market capitalization of $123.13 million and generates $33.82 million in revenue each year. The biopharmaceutical company earns $172.17 million in net income (profit) each year or $2.00 on an earnings per share basis. How can I contact Chimerix? Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146. This page (NASDAQ:CMRX) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.